Project Grant R01AG096489
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- This federal Project Grant award of $509,413.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct research on the role of epitranscriptomic regulation of microglial cells in the development and progression of Alzheimer's disease (AD). The project will investigate how methylation of adenosine residues in mRNA (m6A modification) and its regulatory proteins are altered in the brains of AD patients, and how these changes impact microglial function and the brain's...
- This $745,765 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York aims to investigate the effects of Alzheimer's disease (AD) risk genes and aging on human microglia activity and lipid metabolism. The key focus is on understanding how genetic variants associated with increased AD risk or longevity may impact microglia's ability to clear cholesterol/lipid-rich cellular debris, a critical...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $486,750 project grant to The Jackson Laboratory in Bar Harbor, Maine. The goal of this 2-year grant, with a period of performance from September 1, 2025 to August 31, 2027, is to investigate the impact of age-related clonal hematopoiesis (CH) mutations in peripheral immune cells on the etiology and progression of Alzheimer's disease (AD) pathology. The research will utilize mouse...
- This Project Grant award, valued at $475,377.00, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to The Trustees of Columbia University in the City of New York. The grant aims to determine the functional significance of microglial FOXO3, a key transcription factor, in Alzheimer's disease (AD) pathobiology. The research will investigate the role of FOXO3 in regulating lipid droplet accumulation and interferon-I pathway...
- The National Institute on Aging (NIA) awarded a $188,892 Project Grant (CFDA 93.866 - Aging Research) to the University of Washington to investigate microglial subpopulations that may contribute to resilience against Alzheimer's disease (AD). The goal is to 1) address key gaps in understanding microglial subpopulation responses in resilient individuals, and 2) develop tools and model systems to manipulate specific microglial subpopulations. The researcher will evaluate microglial...
- This $427,625 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the mechanisms by which microgliopathy, a genetic neurological disorder, causes early-onset dementia. The research will investigate how the loss of the DAP12 protein in microglia, the immune cells of the brain, leads to heightened signaling of the RUNX and STAT3 pathways. This dysregulation is hypothesized to disrupt normal microglial functions and induce brain pathology and...
- The Project Grant award titled "ENHANCER-AAVS TO MONITOR AND RESTORE CELL-TYPE SELECTIVE INHIBITORY DEFICITS AND CIRCUIT DYSFUNCTION IN HUMANIZED ALZHEIMER'S DISEASE MODELS" was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The $1,459,072.00 award, granted to the J. David Gladstone Institutes, aims to monitor and manipulate inhibitory interneuron cell populations in mouse models to assess their contribution to...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of a fiber implant for longitudinal, multifunctional deep-brain interfacing in mouse models of Alzheimer's disease (AD). The $683,028 award aims to create a comprehensive bidirectional interface that integrates photoacoustic microscopy, two-photon microscopy, neural stimulation, and drug delivery capabilities to enable long-term monitoring and manipulation of the deep brain...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
This federal Project Grant award of $716,579, awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to investigate the role of microglia, the immune cells of the brain, in the progression of Alzheimer's disease (AD). Specifically, the research aims to genetically dissect the relationships between different activated states of microglia and their involvement in complement-mediated synapse loss, which is a key neurobiological driver of cognitive decline in AD. The project, led by the Jackson Laboratory in Bar Harbor, Maine, leverages various genetically engineered mouse models and cell lineage tracing techniques to elucidate the spatial and temporal coordination of microglia and other cell types in the complement cascade during AD pathogenesis. The ultimate goal is to identify new therapeutic targets to prevent or intervene in synapse loss, a critical unmet need in AD. The award period runs from December 2025 to November 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $716.6k | 12/23/25 |